Pharmagen, Inc. ("Pharmagen"), comprises wholly owned subsidiaries and operating divisions Pharmagen Laboratories (“Labs”), Pharmagen Distribution, and Pharmagen Nutraceuticals. Pharmagen is the leader in innovative solutions to the nation’s sterile pharmaceutical shortage crisis. With a disruptive approach to the pharmaceutical distribution and production model, Pharmagen is meeting the demands of the health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. By connecting with hundreds of hospital partners each day, Pharmagen generates real-time market data on sterile injectable shortages, and sources products within the national supply chain within 24 to 48 hours. If unavailable, Pharmagen produces these pharmaceuticals in its FDA-inspected compounding facility, under Certified ISO Class 5 and 6 sterile environments, employing USP <797> and USP <795>, and the latest cGMP, standards. With QA/QC on every batch, we offer our hospital partners the safest, most affordable pharmaceutical solutions on the market today.
Pharmagen also manufactures and distributes over-the-counter (OTC) branded health supplements. Pharmagen’s innovative approach to OTC is to create suites of products designed to work in conjunction with prescription medications to alleviate side effects or prevent drug interactions. With an aging population, more Americans than ever are on prescription medications. Pharmagen envisions various disease states to be a driving factor in OTC uptake. The company’s first product, Clotamin, is a multivitamin specifically formulated for patients with blood clotting disorders who take blood thinners such as warfarin (Coumadin). Pharmagen is currently analyzing several OTC products that would allow us to become a powerful player in the multi-billion dollar health supplement market.
Stock Symbol: PHRX